You will be redirected to our secure system.
When you need on-site attention, we’re not just here to help, we’re there to help—right by your side.
Individual courses are remarkably effective. But sometimes when you have a specific need, it helps to have expert guidance right in the room with you and your team.
In that case, we’re happy to design a custom training for your entire team, whether online—or on-site.
Learn moreRemember – at checkout you can choose to take this course On-demand. We offer a 10% group discount when you register 2 of more attendees (up to 10). Contact us for larger groups.
The Role of Corrective Action and Preventative Action in Your Quality
System
There has been several form 483’s and warning letters being issued to companies by the FDA as it relates to CAPA investigation because of insufficient or incomplete quality systems procedures applicable to corrective action and preventative action programs (CAPA). Addressing an FDA form 483 with findings associated with CAPA systems must be performed adequately, complete and must provide enough details within the CAPA procedures to ensure an effective CAPA investigational procedure. All failure, deviation or out of specification investigations must be adequately documented, corrected, prevented and checked for corrective action effectiveness through the use of a compliant CAPA investigational system and program. The result of a product investigation impacts the quality of the cGMP manufactured product label claim, to avoid it from being termed adulterated by the FDA which may result in product recalls, complaint and further actions by the FDA.
This 90-minute accredited training will benefit manufacturers of cGMP products in designing an effective, robust and compliant CAPA investigation system in order to avoid FDA or other regulatory bodies inspection findings in these areas. It will also be a great resource to Quality Assurance, Manufacturing, Regulatory Affairs and Quality Control personnel and management within the Pharmaceutical, Biotechnology and Medical Device companies.
This webinar will provide a great resource to Pharmaceutical, Biotechnology and Medical Device Industries personnel within the following
departments:
• Quality Control Personnel
• Manufacturing Personnel
• Senior Management
• Regulatory Affairs Personnel
• Quality Assurance Personnel
• Supplier Quality Personnel
However, if you are already familiar with CAPA and its requirements, you may recommend this webinar to anyone in your company that may require additional knowledge about this subject.
Charity Ogunsanya
(Owner/CEO), Pharmabiodevice Consulting LLC
Charity Ogunsanya has more than 30 years of extensive experience within the Biologics, Pharmaceuticals, Radiopharmaceuticals, Biotechnology and Medical Device Industries and has been the Microbiology, Sterility Assurance, Contamination Control, Aseptic processing, Quality Control Subject Matter Expert (SME) for multiple fortune 100 companies.
She has a Bachelor of Science degree in Microbiology from the University of Benin-Nigeria and has a Masters degree from the Advanced Academic Master's Biotechnology Program at the Johns Hopkins University with concentration in Biotechnology/Biodefense. She is the CEO/ Owner of her consulting firm named Pharma biodevice Consulting LLC. Her consultancy provides support to Biologics, Pharmaceuticals, Radiopharmaceuticals, Biotechnology and Medical Device Industries.